down arrow

Senti Biosciences, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US81726A1007
USD
2.22
0.12 (5.71%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

2.102.23

52 Week

1.267.10
Valuation
Technical
Day's Volume

CASH

112.48 k

Shareholding (Mar 2025)

FII

0.24%

Held by 10 FIIs

DII

81.88%

Held by 3 DIIs

Promoter

15.60%

How big is Senti Biosciences, Inc.?

22-Jun-2025

As of Jun 18, Senti Biosciences, Inc. has a market capitalization of 72.51 million and reported net sales of 0.00 million with a net profit of -54.79 million over the last four quarters. The balance sheet shows shareholder's funds of 50.76 million and total assets of 97.84 million.

As of Jun 18, Senti Biosciences, Inc. has a market capitalization of 72.51 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 0.00 million for the latest four quarters, with a net profit of -54.79 million during the same period.<BR><BR>As of Dec 24, the balance sheet shows shareholder's funds of 50.76 million and total assets amounting to 97.84 million.

Read More

What does Senti Biosciences, Inc. do?

22-Jun-2025

Senti Biosciences, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $14 million and a market cap of $72.51 million. Key metrics include a negative P/E ratio, a 0.00% dividend yield, and a return on equity of -139.41%.

Overview: <BR>Senti Biosciences, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Net Profit: -14 Million (Quarterly Results - Mar 2025) <BR>Market Cap: USD 72.51 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.77 <BR>Return on Equity: -139.41% <BR>Price to Book: 1.92<BR><BR>Contact Details: <BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Read More

Is Senti Biosciences, Inc. overvalued or undervalued?

25-Jun-2025

As of August 13, 2024, Senti Biosciences, Inc. is considered overvalued at $1.99 due to negative financial metrics, including a Price to Book Value of 2.65, an EV to Capital Employed ratio of 8.02, and a year-to-date return of -43.3%, indicating significant operational inefficiencies and underperformance compared to its peers.

As of 13 August 2024, the valuation grade for Senti Biosciences, Inc. has moved from risky to does not qualify, indicating a significant deterioration in its financial standing. The company is currently overvalued given its financial metrics, including a Price to Book Value of 2.65 and an EV to Capital Employed ratio of 8.02, which suggest that investors are paying a premium for its assets despite the lack of profitability. Notably, the company's ROCE stands at a staggering -685.86%, and the ROE is also negative at -139.41%, highlighting severe operational inefficiencies.<BR><BR>In comparison to its peers, Senti Biosciences, Inc. has an EV to EBITDA of -1.29, while Pieris Pharmaceuticals, Inc. and Forte Biosciences, Inc. have EV to EBITDA ratios of -9.6042 and -0.7943, respectively. This indicates that Senti is underperforming relative to its peers in terms of earnings potential. Additionally, the company's recent stock performance has been dismal, with a year-to-date return of -43.3%, significantly underperforming the S&P 500's 2.44% return over the same period. Overall, the combination of negative financial ratios and poor market performance suggests that Senti Biosciences, Inc. is overvalued at its current price of $1.99.

Read More

Is Senti Biosciences, Inc. technically bullish or bearish?

20-Sep-2025

As of August 6, 2025, Senti Biosciences, Inc. has shifted to a bearish trend with weak strength indicators, underperforming the S&P 500 by -60.4% year-to-date compared to its 12.22% return.

As of 6 August 2025, the technical trend has changed from mildly bearish to bearish. The current stance is bearish with a weak strength indicated by the weekly MACD and Dow Theory both showing bearish signals. The daily moving averages also confirm a bearish outlook. The weekly RSI is bullish, but this is offset by the overall bearish sentiment from the other indicators. <BR><BR>In terms of performance, Senti Biosciences, Inc. has significantly underperformed the S&P 500 across all periods, with a year-to-date return of -60.4% compared to the S&P 500's 12.22%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 35 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.67

stock-summary
Return on Equity

-227.10%

stock-summary
Price to Book

1.40

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-15 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
53.63%
0%
53.63%
6 Months
-29.52%
0%
-29.52%
1 Year
-68.91%
0%
-68.91%
2 Years
-49.55%
0%
-49.55%
3 Years
-1.33%
0%
-1.33%
4 Years
-77.58%
0%
-77.58%
5 Years
0%
0%
0.0%

Senti Biosciences, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Senti Biosciences, Inc. technically bullish or bearish?

As of 6 August 2025, the technical trend has changed from mildly bearish to bearish. The current stance is bearish with a weak strength indicated by the weekly MACD and Dow Theory both showing bearish signals. The daily moving averages also confirm a bearish outlook. The weekly RSI is bullish, but this is offset by the overall bearish sentiment from the other indicators. In terms of performance, Senti Biosciences, Inc. has significantly underperformed the S&P 500 across all periods, with a year-to-date return of -60.4% compared to the S&P 500's 12.22%....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-100.00%
EBIT Growth (5y)
-296.03%
EBIT to Interest (avg)
-44.58
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.77
Sales to Capital Employed (avg)
0.03
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
24.86%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.65
EV to EBIT
-1.17
EV to EBITDA
-1.29
EV to Capital Employed
8.02
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-685.86%
ROE (Latest)
-139.41%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Strategic Entities

Domestic Funds

Held in 5 Schemes (2.28%)

Foreign Institutions

Held by 10 Foreign Institutions (0.24%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs -100.00% in Jun 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -31.25% vs 40.11% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-15.30",
          "val2": "-11.90",
          "chgp": "-28.57%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.30",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-14.70",
          "val2": "-11.20",
          "chgp": "-31.25%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -100.00% vs -39.53% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 36.69% vs -67.81% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "2.60",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-54.90",
          "val2": "-61.50",
          "chgp": "10.73%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.40",
          "val2": "-21.80",
          "chgp": "101.83%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-52.80",
          "val2": "-83.40",
          "chgp": "36.69%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "-26,069.90%",
          "chgp": "2,606.99%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-15.30
-11.90
-28.57%
Interest
0.00
0.00
Exceptional Items
0.00
0.30
-100.00%
Consolidate Net Profit
-14.70
-11.20
-31.25%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs -100.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -31.25% vs 40.11% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
2.60
-100.00%
Operating Profit (PBDIT) excl Other Income
-54.90
-61.50
10.73%
Interest
0.00
0.00
Exceptional Items
0.40
-21.80
101.83%
Consolidate Net Profit
-52.80
-83.40
36.69%
Operating Profit Margin (Excl OI)
0.00%
-26,069.90%
2,606.99%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is -100.00% vs -39.53% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 36.69% vs -67.81% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Senti Biosciences, Inc. stock-summary
stock-summary
Senti Biosciences, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."